Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation to Recipients With Limited Donor Engraftment View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

-

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment. A second infusion of unselected donor hematopoietic stem cells (HSC) can result in improvement, but can potentially increase the incidence of graft versus host disease. Cluster of differentiation 34+ (CD34+) selected stem cells depleted of T-cells is an attractive alternative for treatment of poor graft function as it may be associated with less Graft versus Host Disease (GVHD) and enhanced count recovery. The investigators are using the Miltenyi CliniMACS device and CD34 cell selection reagents for the preparation of allogeneic hematopoietic progenitor cell (HPC) transplants for patients who have had prior stem cell transplants and require a stem cell "boost" from the original donor. Detailed Description This is a single-arm, open label, single institution, compassionate study which will enroll patients who are marginally engrafted and transfusion and/or growth factors dependent after allogeneic hematopoietic stem cell transplant (HSCT) regardless of the underlying disease for which the transplant was performed. Study subjects will receive a "booster" infusion of CD34+ cell selected and T-cell depleted G-CSF mobilized apheresis product from the original stem cell donor in order to improve engraftment. The "booster" infusion will be administered without prior conditioning. More... »

URL

https://clinicaltrials.gov/show/NCT02258490

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment. A second infusion of unselected donor hematopoietic stem cells (HSC) can result in improvement, but can potentially increase the incidence of graft versus host disease. Cluster of differentiation 34+ (CD34+) selected stem cells depleted of T-cells is an attractive alternative for treatment of poor graft function as it may be associated with less Graft versus Host Disease (GVHD) and enhanced count recovery. The investigators are using the Miltenyi CliniMACS device and CD34 cell selection reagents for the preparation of allogeneic hematopoietic progenitor cell (HPC) transplants for patients who have had prior stem cell transplants and require a stem cell \"boost\" from the original donor.\n\nDetailed Description\nThis is a single-arm, open label, single institution, compassionate study which will enroll patients who are marginally engrafted and transfusion and/or growth factors dependent after allogeneic hematopoietic stem cell transplant (HSCT) regardless of the underlying disease for which the transplant was performed. Study subjects will receive a \"booster\" infusion of CD34+ cell selected and T-cell depleted G-CSF mobilized apheresis product from the original stem cell donor in order to improve engraftment. The \"booster\" infusion will be administered without prior conditioning.", 
    "id": "sg:clinicaltrial.NCT02258490", 
    "keywords": [
      "CSF", 
      "selected cell", 
      "Homologous Transplantation", 
      "recipient", 
      "engraftment", 
      "hematopoietic stem cell transplantation", 
      "abnormality", 
      "graft function", 
      "infusion", 
      "hematopoietic stem cell", 
      "improvement", 
      "incidence", 
      "Transplant", 
      "host disease", 
      "cluster", 
      "stem cell", 
      "T lymphocyte", 
      "Graft vs Host Disease", 
      "recovery", 
      "Equipment and Supply", 
      "cell selection", 
      "preparation", 
      "patient", 
      "stem cell transplant", 
      "single-arm", 
      "single institution", 
      "transfusion", 
      "growth factor", 
      "hematopoietic stem cell transplant", 
      "disease", 
      "study subject", 
      "CD34+ cell", 
      "T cell", 
      "conditioning"
    ], 
    "name": "Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation to Recipients With Limited Donor Engraftment", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02258490"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00017.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.189967.8", 
        "type": "Organization"
      }
    ], 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1182/blood-2002-05-1615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001129606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/14653240600735784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001664701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1537-2995.2010.02758.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001896641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.transproceed.2004.09.052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004944851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/14653240600620994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011705516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-04-1203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012656960"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2004.05062.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044843130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bcmd.2004.08.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047137489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1703154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048413909", 
          "https://doi.org/10.1038/sj.bmt.1703154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077264340", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082580030", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02258490"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02258490'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02258490'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02258490'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02258490'


 

This table displays all metadata directly associated to this object as RDF triples.

83 TRIPLES      14 PREDICATES      58 URIs      41 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02258490 schema:about anzsrc-for:3048
2 schema:description Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment. A second infusion of unselected donor hematopoietic stem cells (HSC) can result in improvement, but can potentially increase the incidence of graft versus host disease. Cluster of differentiation 34+ (CD34+) selected stem cells depleted of T-cells is an attractive alternative for treatment of poor graft function as it may be associated with less Graft versus Host Disease (GVHD) and enhanced count recovery. The investigators are using the Miltenyi CliniMACS device and CD34 cell selection reagents for the preparation of allogeneic hematopoietic progenitor cell (HPC) transplants for patients who have had prior stem cell transplants and require a stem cell "boost" from the original donor. Detailed Description This is a single-arm, open label, single institution, compassionate study which will enroll patients who are marginally engrafted and transfusion and/or growth factors dependent after allogeneic hematopoietic stem cell transplant (HSCT) regardless of the underlying disease for which the transplant was performed. Study subjects will receive a "booster" infusion of CD34+ cell selected and T-cell depleted G-CSF mobilized apheresis product from the original stem cell donor in order to improve engraftment. The "booster" infusion will be administered without prior conditioning.
3 schema:keywords CD34+ cell
4 CSF
5 Equipment and Supply
6 Graft vs Host Disease
7 Homologous Transplantation
8 T cell
9 T lymphocyte
10 Transplant
11 abnormality
12 cell selection
13 cluster
14 conditioning
15 disease
16 engraftment
17 graft function
18 growth factor
19 hematopoietic stem cell
20 hematopoietic stem cell transplant
21 hematopoietic stem cell transplantation
22 host disease
23 improvement
24 incidence
25 infusion
26 patient
27 preparation
28 recipient
29 recovery
30 selected cell
31 single institution
32 single-arm
33 stem cell
34 stem cell transplant
35 study subject
36 transfusion
37 schema:name Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation to Recipients With Limited Donor Engraftment
38 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02258490
39 schema:sdDatePublished 2019-03-07T15:25
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Na33bc9535bdc4cf4a1428779ea3b5753
42 schema:sponsor https://www.grid.ac/institutes/grid.189967.8
43 schema:subjectOf sg:pub.10.1038/sj.bmt.1703154
44 https://app.dimensions.ai/details/publication/pub.1077264340
45 https://app.dimensions.ai/details/publication/pub.1082580030
46 https://doi.org/10.1016/j.bcmd.2004.08.016
47 https://doi.org/10.1016/j.transproceed.2004.09.052
48 https://doi.org/10.1080/14653240600620994
49 https://doi.org/10.1080/14653240600735784
50 https://doi.org/10.1111/j.1365-2141.2004.05062.x
51 https://doi.org/10.1111/j.1537-2995.2010.02758.x
52 https://doi.org/10.1182/blood-2002-04-1203
53 https://doi.org/10.1182/blood-2002-05-1615
54 schema:url https://clinicaltrials.gov/show/NCT02258490
55 sgo:license sg:explorer/license/
56 sgo:sdDataset clinical_trials
57 rdf:type schema:MedicalStudy
58 Na33bc9535bdc4cf4a1428779ea3b5753 schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
61 rdf:type schema:DefinedTerm
62 sg:pub.10.1038/sj.bmt.1703154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048413909
63 https://doi.org/10.1038/sj.bmt.1703154
64 rdf:type schema:CreativeWork
65 https://app.dimensions.ai/details/publication/pub.1077264340 schema:CreativeWork
66 https://app.dimensions.ai/details/publication/pub.1082580030 schema:CreativeWork
67 https://doi.org/10.1016/j.bcmd.2004.08.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047137489
68 rdf:type schema:CreativeWork
69 https://doi.org/10.1016/j.transproceed.2004.09.052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004944851
70 rdf:type schema:CreativeWork
71 https://doi.org/10.1080/14653240600620994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011705516
72 rdf:type schema:CreativeWork
73 https://doi.org/10.1080/14653240600735784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001664701
74 rdf:type schema:CreativeWork
75 https://doi.org/10.1111/j.1365-2141.2004.05062.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1044843130
76 rdf:type schema:CreativeWork
77 https://doi.org/10.1111/j.1537-2995.2010.02758.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001896641
78 rdf:type schema:CreativeWork
79 https://doi.org/10.1182/blood-2002-04-1203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012656960
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1182/blood-2002-05-1615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001129606
82 rdf:type schema:CreativeWork
83 https://www.grid.ac/institutes/grid.189967.8 schema:Organization
 




Preview window. Press ESC to close (or click here)


...